Fineline Cube

Follow:
14398 Articles
Humanwell Healthcare Secures NMPA Approval for Clinical Trial of HW211026 to Treat Actinic Keratosis
CompanyDrug

Humanwell Healthcare Secures NMPA Approval for Clinical Trial of HW211026 to Treat Actinic Keratosis

Thermo Fisher Faces FDA Scrutiny Over Syringe Air Bubble Protocols at North Carolina Plant
Company

Thermo Fisher Faces FDA Scrutiny Over Syringe Air Bubble Protocols at North Carolina Plant

United Laboratories' TUL12101 Eye Drops Enter Phase IIa Clinical Trial for Dry Eye Syndrome
CompanyDrug

United Laboratories’ TUL12101 Eye Drops Enter Phase IIa Clinical Trial for Dry Eye Syndrome

3D Medicines' Envafolimab Earns NMPA Breakthrough Designation for TMB-H Solid Tumors
CompanyDrug

3D Medicines’ Envafolimab Earns NMPA Breakthrough Designation for TMB-H Solid Tumors

Roche's Vabysmo Receives NMPA Approval for Macular Edema Treatments in China
CompanyDrug

Roche’s Vabysmo Receives NMPA Approval for Macular Edema Treatments in China

Intas Pharmaceuticals Receives FDA Approval for Biosimilar Stelara, Expanding Treatment Options for Autoimmune Diseases
CompanyDrug

Intas Pharmaceuticals Receives FDA Approval for Biosimilar Stelara, Expanding Treatment Options for Autoimmune Diseases

Beijing Aims to Build a Leading Cell and Gene Therapy Hub by 2026 with New Action Plan
Policy / Regulatory

Beijing Aims to Build a Leading Cell and Gene Therapy Hub by 2026 with New Action Plan

RemeGen's Disitamab Vedotin Receives Priority Review for New Indication in Breast Cancer by China's NMPA
CompanyDrug

RemeGen’s Disitamab Vedotin Receives Priority Review for New Indication in Breast Cancer by China’s NMPA

Lundbeck Secures Rights to Bexicaserin with Acquisition of Longboard Pharmaceuticals
CompanyDeals

Lundbeck Secures Rights to Bexicaserin with Acquisition of Longboard Pharmaceuticals

Stemirna Therapeutics, Once a Leading mRNA Developer in China, Enters Bankruptcy Proceedings
Company

Stemirna Therapeutics, Once a Leading mRNA Developer in China, Enters Bankruptcy Proceedings

Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders
Legal / IP

Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders

AstraZeneca and Daiichi Sankyo’s Enhertu Receives Fourth Indication Approval in China
CompanyDrug

AstraZeneca and Daiichi Sankyo’s Enhertu Receives Fourth Indication Approval in China